|
kEUR |
2024 |
2023 |
Change |
|
|
|
|
|
|
Revenue 2 |
336,792 |
320,372 |
5.1% |
|
EBITDA |
25,350 |
-5,999 |
- 3 |
|
EBITDA in % of revenue |
7.5% |
-1.9% |
9.4 ppts |
|
Operating result (EBIT) |
-7,364 |
-36,468 |
79.8% |
|
Operating result (EBIT) in % of revenue |
-2.2% |
-11.4% |
9.2 ppts |
|
Result for the year |
-19,564 |
-51,440 |
62.0% |
|
Result for the year in % of revenue |
-5.8% |
-16.1% |
10.2 ppts |
|
Earnings per share (EUR), basic |
-0.59 |
-1.56 |
62.0% |
|
Return on net operating assets (RONOA) |
-1.6% |
-8.5% |
6.9 ppts |
|
Cash and cash equivalents (end of year) |
68,277 |
95,706 |
-28.7% |
|
Net cash flow from operating activities |
89,399 |
36,485 |
145.0% |
|
Capital expenditures |
87,839 |
54,890 |
60.0% |
|
Capital expenditures in % of revenue |
26.1% |
17.1% |
8.9 ppts |
|
Total assets (end of year) |
756,576 |
689,088 |
9.8% |
|
Equity ratio (end of year) |
47.2% |
55.3% |
-8.1 ppts |
|
Employees (# of FTEs, average) |
1,291 |
1,202 |
7.4% |
1 This table and report include references to operational indicators and alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes for the Group’s consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, please refer to the section “Definitions and reconciliations” of this report.
2 For revenue by business area, refer to Note 3 of the consolidated financial statements. For the purpose of this report and to discuss business drivers more concisely, revenue of the business areas Contract Manufacturing and Generics & Cosmetics have been combined into “Commercial revenue”, while revenue in the business area Custom Projects is labelled “Development revenue”.
3 Change in % not meaningful.